You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

CLINICAL TRIALS PROFILE FOR SECRETIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Secretin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036231 ↗ Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction Terminated Repligen Corporation Phase 3 2002-04-01 The purpose of the study is to determine the effect of multiple doses of secretin on autism.
NCT00036244 ↗ Synthetic Human Secretin in Children With Autism Completed Repligen Corporation Phase 3 2002-04-01 The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
NCT00065962 ↗ Secretin for the Treatment of Autism Completed National Institute on Deafness and Other Communication Disorders (NIDCD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 ↗ Secretin for the Treatment of Autism Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00216294 ↗ Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder Completed Repligen Corporation Phase 2 2005-02-01 The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Secretin

Condition Name

Condition Name for Secretin
Intervention Trials
Chronic Pancreatitis 7
Pancreatic Cancer 5
Autism 3
Obesity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Secretin
Intervention Trials
Pancreatitis 11
Pancreatic Neoplasms 8
Pancreatitis, Chronic 8
Autistic Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Secretin

Trials by Country

Trials by Country for Secretin
Location Trials
United States 37
Denmark 3
United Kingdom 3
Finland 1
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Secretin
Location Trials
Ohio 5
Massachusetts 4
Indiana 4
New York 3
New Hampshire 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Secretin

Clinical Trial Phase

Clinical Trial Phase for Secretin
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2/Phase 3 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Secretin
Clinical Trial Phase Trials
Completed 20
Terminated 5
Unknown status 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Secretin

Sponsor Name

Sponsor Name for Secretin
Sponsor Trials
ChiRhoClin, Inc. 6
Repligen Corporation 6
Massachusetts General Hospital 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Secretin
Sponsor Trials
Other 36
Industry 14
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Secretin

Introduction to Secretin

Secretin is a synthetic peptide that acts as an agonist for the secretin receptor. It is primarily used in medical diagnostics, particularly for assessing exocrine pancreas function and in the management of certain gastrointestinal disorders.

Clinical Trials and Therapeutic Uses

Diagnostic Imaging

Secretin has been extensively studied for its role in enhancing magnetic resonance cholangiopancreatography (MRCP) and other diagnostic imaging techniques for the pancreas. A notable study by Repligen Corporation reported positive Phase 2 clinical trial results, where secretin aided in the detection of structural abnormalities of the pancreas. This study was conducted with protocols approved by the U.S. Food and Drug Administration (FDA) and demonstrated the potential for secretin to improve MRI imaging of the pancreas[3].

Gastrointestinal Disorders

Secretin is used to assess pancreatic function, particularly in conditions like pancreatitis. Clinical trials have shown that patients with pancreatic diseases have a reduced fluid production response to secretin, which can be a valuable diagnostic tool[3].

Other Indications

There have been exploratory studies on the use of secretin in other conditions, such as obsessive-compulsive disorder (OCD). A Phase 2 study in the US investigated the effects of secretin on OCD, although the results were not widely reported as successful[1].

Market Analysis

Current Market Size and Growth

The global synthetic human secretin market was valued at USD 9.37 million in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.6% and is expected to surpass USD 15.30 million by 2031. This growth is driven by increasing disposable income globally and the rising prevalence of pancreatitis and other gastrointestinal disorders[2].

Regional Market Segments

The market is segmented by region, with North America projected to dominate due to the high incidence of pancreatitis, affecting around 80,000 people in the US annually. The Middle East and Africa are expected to be rapidly growing regions due to increasing hospitalizations for acute pancreatitis and pancreatic cancer, along with advances in diagnosis and critical care management[2].

End-User Segments

The market is also segmented by end-users, including academics, hospitals, and clinics. These segments are crucial as they drive the demand for synthetic human secretin for diagnostic and therapeutic purposes[2].

Market Drivers and Restraints

Drivers

  • Increasing Prevalence of Pancreatitis: The rising number of cases of pancreatitis and other gastrointestinal disorders is a significant driver for the market.
  • Advances in Diagnostic Techniques: Improvements in MRI imaging and other diagnostic methods that utilize secretin are boosting market growth.
  • Growing Disposable Income: Higher disposable incomes globally are leading to increased healthcare spending, which benefits the synthetic human secretin market[2].

Restraints

  • Regulatory Challenges: The need for FDA approval and stringent regulatory requirements can slow market growth.
  • Cost and Accessibility: The cost of synthetic human secretin and its availability can be barriers to widespread adoption, especially in developing regions[5].

Market Projections

Forecasted Growth

The synthetic human secretin market is expected to experience significant growth from 2023 to 2031, driven by the factors mentioned above. The market size is anticipated to expand substantially, reflecting the increasing demand for diagnostic and therapeutic applications[2].

Geographical Expansion

North America is expected to remain the dominant region, but the Middle East and Africa are projected to show rapid growth due to improving healthcare infrastructure and increasing awareness of gastrointestinal disorders[2].

Key Players and Market Trends

Market Players

Several key players are involved in the development and distribution of synthetic human secretin. These companies are focused on improving the efficacy and availability of the drug, which is driving market competition and innovation[2].

Market Trends

The trend towards more accurate and non-invasive diagnostic techniques is a key driver for the market. Additionally, the integration of synthetic human secretin into routine diagnostic protocols in hospitals and clinics is expected to continue, further boosting market growth[5].

Conclusion

Secretin, as a synthetic peptide, holds significant potential in the medical field, particularly in diagnostic imaging and the management of gastrointestinal disorders. With a projected market size set to surpass USD 15.30 million by 2031, the future looks promising for this drug.

"Growing disposable income globally is expected to boost the market growth during the forecast period."[2]

Key Takeaways

  • Clinical Trials: Secretin has shown positive results in Phase 2 clinical trials for diagnostic imaging of the pancreas and other gastrointestinal disorders.
  • Market Growth: The global synthetic human secretin market is expected to grow at a CAGR of 5.6% from 2022 to 2031.
  • Regional Dominance: North America is projected to dominate the market, with the Middle East and Africa showing rapid growth.
  • End-User Demand: Academics, hospitals, and clinics drive the demand for synthetic human secretin.
  • Market Drivers: Increasing prevalence of pancreatitis, advances in diagnostic techniques, and growing disposable income are key drivers.

FAQs

What is the primary use of synthetic human secretin in medical diagnostics?

Synthetic human secretin is primarily used to assess exocrine pancreas function and in the management of certain gastrointestinal disorders, such as pancreatitis.

Which region is expected to dominate the global synthetic human secretin market?

North America is projected to dominate the global synthetic human secretin market due to the high incidence of pancreatitis and other gastrointestinal disorders.

What is the expected market size of synthetic human secretin by 2031?

The global synthetic human secretin market is expected to surpass USD 15.30 million by 2031.

What are the key drivers for the growth of the synthetic human secretin market?

The key drivers include the increasing prevalence of pancreatitis, advances in diagnostic techniques, and growing disposable income globally.

Which other conditions are being explored for the use of secretin?

Besides gastrointestinal disorders, secretin has been explored for use in conditions such as obsessive-compulsive disorder (OCD), although these studies are less prominent.

Sources

  1. Patsnap Synapse - Secretin - Drug Targets, Indications, Patents
  2. PR Newswire - Global Synthetic Human Secretin Market to Surpass USD 15.30 Million by 2031
  3. FierceBiotech - Repligen Corporation Reports Positive Phase 2 Clinical Trial Results of Secretin for MRI Imaging of the Pancreas
  4. Singularity Hub - Four Clinical Trials We're Watching That Could Change Medicine in 2025
  5. Market Research Intellect - Global Synthetic Human Secretin Sales Market Size, Scope And Forecast

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.